Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > Chuikyo Debate on FY2026 Drug Pricing Reform
Chuikyo Debate on FY2026 Drug Pricing Reform
-
Chuikyo Discusses Lower Prices for Low-Novelty Drugs, PMP Criteria, Re-Pricing
November 20, 2025
-
Chuikyo Split over How to Ease Negative Margins
November 20, 2025
-
Providers Urging Possible Price Measures over Packaging Misalignment
November 20, 2025
-
Providers Push to Expand 2% Buffer Zone in Drug Price Revisions as Costs Rise
November 20, 2025
-
Japan Moves to Advance “G1” Price Cuts by 5 Years under Proposed LLP Overhaul
November 20, 2025
-
Chuikyo Split over Higher Copays under LLP Scheme; Payer Push Meets Provider Caution
November 17, 2025
-
Chuikyo Backs Halving Profit Coefficient for Conditionally Approved Regenerative Medicines
November 13, 2025
-
Industry Opposes Deeper CEA Price Cuts for “Cost-Increase” Products
November 13, 2025
-
Tepid Exchanges at Chuikyo over Public-Private Working Group Report
November 6, 2025
-
Japan Mulls Full Overhaul of LLP Rule under FY2026 Drug Pricing Reform
October 30, 2025
-
Exclude High-Price-Gap Products from Unprofitable Drug Re-Pricing: Chuikyo
October 30, 2025
-
FIRM Urges Continued Premiums for Conditionally Approved Regenerative Medicines
October 30, 2025
-
Japan Eyes Review of Generic Price Bands, Brand-Based Revisions for Tier A Products
October 30, 2025
-
No Objections to Expanding Reimbursement Incentives for Biosimilars: Chuikyo
October 20, 2025
-
Payers, Providers Clash over Fate of Fee Premiums for Generic Use
October 20, 2025
-
Japan to Clarify Criteria for Upward Price Adjustments under CEA Scheme
October 16, 2025
-
Deeper CEA Price Cuts Mooted for “Cost Increase” Products: FY2026 Reform Debate
October 16, 2025
-
Chuikyo Urges Stricter Pricing Rules for Conditionally Approved Regenerative Medicines
October 16, 2025
-
Chuikyo Frowns on Industry Calls for Scrapping Huge-Seller Re-Pricing, Spillovers
October 9, 2025
-
Chuikyo Wary of Revising “Zero” Premium Rule for Low Cost Disclosure
October 9, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s drug pricing panel on November 19 discussed a wide range of potential pricing changes related to patent-protected medicines, including…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…